Drug maker Glenmark Generics today said it has received a final approval from the US health regulator to sell anti-inflammatory skin ointment, mometasone furorate in the American market.
"Glenmark Generics Inc, USA, a subsidiary of the company has been granted final approval by United States Food and Drug Administration (USFDA) for marketing and distribution of mometasone furorate tropical solution USP, 0.1 per cent in the US market." the company said in a statement.
Mometasone furorate is a medium potency glucocorticoid steroid used in reducing inflammation of the skin. It has anti -inflammatory, antipruitic (relieving itching) and vasoconstrictive (narrowing of blood vessels) properties. This is available in both cream and ointment forms.
The company quoting IMS Health said the total market sales of its mometasone furorate product line is approximately $25 million for the 12-month period ended June 30, 2010.
Glenmark has received nine final and two tentative approvals to date in this fiscal.
"The company is authorised to distribute 61 products in the US market and has 45 pending applications with USFDA," it said.